LucidScope
AI is already answering questions about your brand. LucidScope shows you what it’s saying, and why.
LucidScope evaluates how leading AI systems respond to real-world questions about your company, products, indications, and competitors.
It maps visibility and positioning in AI-generated answers, traces the sources shaping those answers, and highlights gaps where evidence is missing, outdated, or misrepresented.
What you can do with LucidScope:
-
Perception Mapping: Compare how AI positions your brand versus key competitors.
- See how AI frames your brand versus competitors, by theme and attribute.
-
Answers Mapping: See how models answer the same stakeholder questions, and where they diverge.
- View side-by-side model answers to your key questions, with differences highlighted.
-
Source Tracing: Identify which websites and documents are shaping AI answers, and where to intervene.
- Understand which domains and documents drive the answers, and what’s missing.
-
Launch and campaign monitoring: Track changes over time across models, markets, and topics.
- Monitor shifts in positioning, key claims, and cited sources (you vs competitors).
Want to see what AI is saying about your brand? Request an AI Answer Audit.
You’ll receive a short report covering Perception, Answers, Source Tracing, and Zero-click gaps.
Already evaluating tools? Test LucidScope.
Questions or feedback? Email us anytime.
January 3, 2026
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan
January 2, 2026
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
January 2, 2026
Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore
January 1, 2026
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
January 1, 2026
Rare Disease 2025 Review: From Orphan Innovation to a System-Level Stress Test
December 31, 2025
Immunology 2025 Review: From Mechanism Proliferation to Platform Discipline
December 30, 2025
Endocrinology 2025 Review: Outcomes, Access, and Earlier Intervention
December 30, 2025
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
December 29, 2025